425 related articles for article (PubMed ID: 20944680)
1. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
2. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
3. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
4. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ΞΆ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
5. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
6. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
[TBL] [Abstract][Full Text] [Related]
7. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
8. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
9. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
11. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.
Bridgeman JS; Hawkins RE; Bagley S; Blaylock M; Holland M; Gilham DE
J Immunol; 2010 Jun; 184(12):6938-49. PubMed ID: 20483753
[TBL] [Abstract][Full Text] [Related]
12. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.
Hombach AA; Chmielewski M; Rappl G; Abken H
Hum Gene Ther; 2013 Mar; 24(3):259-69. PubMed ID: 23350854
[TBL] [Abstract][Full Text] [Related]
14. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
15. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
16. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
18. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.
Ghiotto-Ragueneau M; Battifora M; Truneh A; Waterfield MD; Olive D
Eur J Immunol; 1996 Jan; 26(1):34-41. PubMed ID: 8566081
[TBL] [Abstract][Full Text] [Related]
20. CD28 costimulation is required not only to induce IL-12 receptor but also to render janus kinases/STAT4 responsive to IL-12 stimulation in TCR-triggered T cells.
Park WR; Park CS; Tomura M; Ahn HJ; Nakahira Y; Iwasaki M; Gao P; Abe R; Hamaoka T; Fujiwara H
Eur J Immunol; 2001 May; 31(5):1456-64. PubMed ID: 11465102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]